← all works
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Cystic Fibrosis Research Advances
- Field
- Medicine
- Canadian institutions
- University of TorontoSt. Michael's Hospital
- Funders
- National Center for Advancing Translational SciencesNational Institute of Diabetes and Digestive and Kidney DiseasesSeattle Children's Research InstituteNational Heart, Lung, and Blood InstituteVertex PharmaceuticalsNational Institutes of HealthCystic Fibrosis Foundation Therapeutics
- Keywords
- IvacaftorCystic fibrosisRegimenMedicineDouble blindInternal medicineMutationClinical trialGeneticsAlternative medicinePathologyBiologyCystic fibrosis transmembrane conductance regulatorPlacebo
- Has abstract in OpenAlex
- no